BRISTOL MYERS SQUIBB CO
CELG-RIDrugs in Pipeline
249
Phase 3 Programs
125
Upcoming Catalysts
13
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
14 upcoming, 5 past
Opdivo
Renal Cell Carcinoma
Lithium
Bipolar Disorder Type I With Mania
Atazanavir/Ritonavir
HIV
Cetuximab
Squamous Cell Carcinoma of the Head and Neck
Stavudine
HIV Infections
Mavacamten
Cardiomyopathy, Hypertrophic
Abatacept
Rheumatoid Arthritis
Entecavir
Hepatitis B, Chronic
Cisplatin
Non Small Cell Lung Cancer
Carboplatin
Pediatric Solid Tumors
Elotuzumab
Multiple Myeloma
Adalimumab
Rheumatoid Arthritis
Mezigdomide
Relapsed or Refractory Multiple Myeloma
Enoxaparin
Deep Vein Thrombosis
Epoetin Alfa
Myelodysplastic Syndromes
Pegylated-Interferon-lambda
Hepatitis C Virus
Apixaban
Lymphoma
dasatinib
Myeloid Leukemia, Chronic, Accelerated Phase
Paclitaxel
Breast Cancer
Muraglitazar
Metabolics Diabetes Nos
Atazanavir + Ritonavir
Human Immunodeficiency Virus (HIV) Infections
Sorafenib
Hepatocellular Carcinoma
SAR302503
Hematopoietic Neoplasm
Irbesartan monotherapy
Hypertension
Atazanavir Sulphate
HIV
Pomalidomide
Multiple Myeloma
Asunaprevir (ASV)
Hepatitis C Virus
Antidepressant + Aripiprazole
Major Depressive Disorder
Asunaprevir
Hepatitis C
DCV
Hepatitis C
Relatlimab
Advanced Gastric Cancer
Daclatasvir
Hepatitis C Infection
BMS-986205
Advanced Cancer
Oral Azacitidine
Myelodysplastic Syndromes
Atazanavir (immediate switch)
HIV Infections
Cabozantinib
Renal Cell Carcinoma
Atazanavir
HIV Infections
Lamivudine/Zidovudine
HIV Infections
Peg-interferon Alfa-2a
Hepatitis C Virus
Gemcitabine
Stage IV or Recurrent Non-Small Cell Lung Cancer
Iza-bren
Urothelial Cancer
vinflunine
Transitional Cell Carcinoma
rHuPH20
Melanoma
Bempegaldesleukin
Bladder Cancer
Pemetrexed
Mesothelioma, Malignant
Fluorouracil
Various Advanced Cancer
Xanomeline/Trospium Chloride Capsule
Alzheimer Disease
Iberdomide
Multiple Myeloma
Sunitinib
Advanced Renal Cell Carcinoma
Deucravacitinib
Psoriatic Arthritis
Atazanvir/ritonavir + efavirenz
HIV Infections
Belatacept
Renal Transplantation
Tacrolimus
Renal Allograft Recipients
PEG-Interferon alfa 2a
Hepatitis C, Genotype 1
Docetaxel
Non-Small Cell Lung Cancer
Double-blind Abatacept
Rheumatoid Arthritis
BMS-986165
Psoriasis
KarXT
Alzheimer Disease
Xanomeline/Trospium Chloride
Mania
Efavirenz
HIV Infections
Xanomeline Enteric Capsule
Alzheimer Disease
BMS-790052 (NS5A Replication Complex Inhibitor)
Hepatitis C
DCV 3DAA
Hepatitis C Virus Infection
Atazanavir + ritonavir + tenofovir + nucleoside
HIV Infections
BMS-986504
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Pumitamig
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
Rheumatoid Arthritis
Capecitabine
Gastric Cancer
Leucovorin
Metastatic Colorectal Cancer
BMS-936558
Unresectable or Metastatic Melanoma
Videx EC
HIV Infections
Etoposide
Small Cell Lung Carcinoma
Apremilast
Psoriatic Arthritis
Ustekinumab
Plaque Psoriasis
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)
Rheumatoid Arthritis
Tenofovir
Chronic Hepatitis B
Oxaliplatin
Colorectal Cancer
Imatinib
Chronic Myeloid Leukemia
Telaprevir
Hepatitis C
Cyclosporine (CsA)
Kidney Transplantation
Xanomeline and Trospium Chloride Capsules
Schizophrenia
MDX-010 (anti-CTLA4) monoclonal antibody
Melanoma
Paclitaxel and carboplatin
Carcinoma, Non-Small-Cell Lung
Pegylated interferon lambda (pegIFNλ)
Hepatitis C Virus (HCV)
Prednisone
Prostate Cancer
Irbesartan
Atrial Fibrillation
stavudine, efavirenz, lamivudine
HIV Infections
Ribavirin
Hepatitis C
Methotrexate
Rheumatoid Arthritis
DCV/ASV/BMS-791325
Hepatitis C Virus
Subcutaneous (SC) Abatacept
Rheumatoid Arthritis (RA)
Dacarbazine
Melanoma
Everolimus
Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Peginterferon Alfa-2a
Hepatitis C
pexacerfont
Generalized Anxiety Disorder
Didanosine
HIV Infections
Methotrexate (MTX)
Rheumatoid Arthritis (RA)
Irbesartan/HCTZ
Hypertension
Peginterferon Lambda-1a
Hepatitis C Virus (HCV)
atazanavir/ritonavir +2 NRTIs (immediate Switch Group)
HIV Infections
Atazanavir powder
HIV Infections
BMS-986353
Systemic Sclerosis
Glucovance (metformin HCl/glyburide)
Diabetes Mellitus, Non-Insulin-Dependent
ATV
HIV Infections
Atazanavir+ritonavir
HIV Infections
Lenalidomide
Multiple Myeloma
Bortezomib
Multiple Myeloma
Nelfinavir mesylate
HIV Infections
Tanespimycin
Advanced Malignancies
Brivanib
Hepato Cellular Carcinoma (HCC)
BMS-986278
Idiopathic Pulmonary Fibrosis
Sofosbuvir
Hepatitis C
Sorivudine
HIV Infections
KarX-EC
Alzheimer's Disease
Pioglitazone
Type 2 Diabetes Mellitus
warfarin
Venous Thrombosis
Adefovir
Hepatitis B, Chronic
Cyclosporin A
Renal Transplantation
Luspatercept
Myelodysplastic Syndromes
Acetylsalicylic acid
Atrial Fibrillation
abatacept (ABA)
Ulcerative Colitis
pegIFNα-2b
Hepatitis C Virus Infection
Temozolomide
Brain Cancer
nab-Paclitaxel
Non-Small Cell Lung Cancer
Abatacept subcutaneous
Polymyositis
Ozanimod
Multiple Sclerosis, Relapsing-Remitting
Aurexis® (tefibazumab)
Staphylococcus Aureus
Aurexis®
Staphylococcus Aureus Bacteremia
branebrutinib
Autoimmune Disorder
Vitamin K Antagonist (VKA)
Thrombosis
Cabazitaxel
Prostate Cancer
Letrozole
Metastatic Breast Cancer
CXL-1020
Heart Failure
Fulvestrant
Advanced Breast Cancer
Oral Taxane
Non-small Cell Lung Cancer
BMS-986253
Cancer
BMS-986322
Psoriasis
Doxorubicin
Hodgkin Disease
Pegylated Interferon Lambda
Hepatitis C
BMS-986490
Advanced Solid Tumors
Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
HIV Infections
MYK-491
Heart Failure With Reduced Ejection Fraction
BMS-986369
Relapsed or Refractory T-cell Lymphomas
5-fluorouracil (5-FU)
Colorectal Cancer
Peginterferon alpha-2a
Hepatitis C Infection
BMS-777607
Advanced Solid Tumors
Exemestane + Dasatinib
Breast Cancer
Dasatinib 100 mg
Breast Cancer
BMS-986207
Broad Solid Tumor
PSI-7977
Chronic Hepatitis C
Megestrol acetate
Anorexia
Fedratinib
Primary Myelofibrosis
200 mg INX-08189 Fasted
Hepatitis C
BMS-582949
Vascular Diseases
unfractionated heparin (UFH)
Antithrombotic
Cobimetinib
Microsatellite Unstable Colorectal Cancer
MORAb-202
Neoplasms, Ovarian
BMS-986523
Advanced Solid Malignancies
BMS-986259
Acute Decompensated Heart Failure
BMS-986036
Non-Alcoholic Steatohepatitis
Afimetoran
Systemic Lupus Erythematosus
MDX-010
Breast Cancer
BMS-823778
Dyslipidemia
Lirilumab
Non-Hodgkin's Lymphoma
BMS-986004 75 mg IV
Immune Thrombocytopenic Purpura
Vemurafenib
Melanoma
Duloxetine
Depression
MDX-1100
Rheumatoid Arthritis
BMS-986231
Cardiac Failure
BMS-986213
Advanced Solid Tumors
Trametinib
Cancer
KOS-1584
Non-Small Cell Lung Cancer
BMS-986158
Myelofibrosis
BMS-908662
Colorectal Cancer
INX-08189 50 mg
Healthy
BMS-986020
Idiopathic Pulmonary Fibrosis
BMS-830216
Obesity
Strata 1 CXL-1020
Heart Failure
carboplatin + irinotecan
Neoplasms
BMS-986340
Cervical Cancer
Anastrozole
Breast Cancer
BMS-986446
Alzheimer Disease, Early Onset
BMS-936557 (Anti-IP-10 Antibody)
Crohn's Disease
BMS-820836
Depression
BMS-770767
Diabetes Type 2
Pegylated-interferon alfa-2a
Chronic Hepatitis C
SAR302503 (TG101348)
Myelofibrosis
pegIFN
Hepatitis B Virus
HNO Donor
Heart Failure
BMS-986435
Heart Failure
Thalidomide
Relapsed and/or Refractory Multiple Myeloma
brivanib (active)
Hepatocellular Carcinoma (HCC)
ixabepilone
Esophageal Cancer
BMS-708163
Alzheimer's Disease
BMS-954561
Diabetic Peripheral Neuropathic Pain
CCR2 Antagonist
Type 2 Diabetes
Cyclophosphamide
Breast Cancer
BMS-790052
Hepatitis C Infection
BMS-986142
Rheumatoid Arthritis
CC-92480
Multiple Myeloma
BMS-986507
Lung Cancer
MDX-010 (CTLA-4)
Melanoma
Cabiralizumab
Advanced Pancreatic Cancer
CXL-1427
Heart Failure
Peginterferon α-2a
Hepatitis C
BMS-986012 (anti-fucosyl-GM1)
Small Cell Lung Cancer
BMS-986449
Advanced Solid Tumors
BMS-986482
Advanced Solid Tumors
BMS-791325
Hepatitis C Virus
Pegylated interferon alfa-2a
Hepatitis C Virus
BMS-986156
Solid Tumors
MDX-010 / MDX-010 + Docetaxel
Prostate Cancer
Lamivudine
Hepatitis B Virus
BMS-986458
Relapsed/Refractory Non-Hodgkin Lymphoma
BMS-986517
Solid Tumours
Cyclosporine
Graft Rejection
Daratumumab
Advanced Cancer
BMS-562086
Irritable Bowel Syndrome
Irinotecan
Colorectal Cancer (CRC)
BMS-986263
Hepatic Cirrhosis
Thymoglobulin
Kidney Transplantation
INX-08189 50 mg QD X 5 days
Healthy
BMS-690514
Non-Small-Cell Lung Carcinoma
Cyclosporine A
Renal Transplant
bendamustine
Hodgkin Disease
Elotuzumab (BMS-901608)
Multiple Myeloma
BMS-986012
Extensive-stage Small Cell Lung Cancer
Ritonavir
HIV Infections
BMS-833923
Leukemia
BMS-986165 Dose A
Active Psoriatic Arthritis
Dexamethasone
Multiple Myeloma
Imzokitug
Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Abatacept (BMS-188667)
Rheumatoid Arthritis
BMS-754807
Breast Cancer
BMS-986315
Advanced Solid Tumor
BMS-986288
Advanced Cancer
BMS-986470
Anemia, Sickle Cell
BMS-790052 (NS5A Inhibitor)
Hepatitis C
BMS-986525
Relapsed/Refractory Small Cell Lung Cancer
BMS-813160
Advanced Cancer
Sirolimus
Disorder Related to Renal Transplantation
BMS-986249
Advanced Cancer
BMS-914392
Atrial Fibrillation
BMS-650032
Hepatitis C Virus
CC-486
Leukemia, Myeloid, Acute
Erlotinib
Non Small Cell Lung Cancer
Anti-CD137 (4-1BB) (BMS-663513)
Melanoma
BMS-986141
Thrombosis
Simeprevir
Hepatitis C Virus
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Opdivo | Approved | Renal Cell Carcinoma | - | - |
Lithium | Phase 3 | Bipolar Disorder Type I With Mania | - | - |
Atazanavir/Ritonavir | Phase 3 | HIV | - | - |
Cetuximab | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | - | - |
Stavudine | Phase 3 | HIV Infections | - | - |
Mavacamten | Phase 3 | Cardiomyopathy, Hypertrophic | - | - |
Abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
Entecavir | Phase 3 | Hepatitis B, Chronic | - | - |
Cisplatin | Phase 3 | Non Small Cell Lung Cancer | - | - |
Carboplatin | Phase 3 | Pediatric Solid Tumors | - | - |
Elotuzumab | Phase 3 | Multiple Myeloma | - | - |
Adalimumab | Phase 3 | Rheumatoid Arthritis | - | - |
Mezigdomide | Phase 3 | Relapsed or Refractory Multiple Myeloma | - | - |
Enoxaparin | Phase 3 | Deep Vein Thrombosis | - | - |
Epoetin Alfa | Phase 3 | Myelodysplastic Syndromes | - | - |
Pegylated-Interferon-lambda | Phase 3 | Hepatitis C Virus | - | - |
Apixaban | Phase 3 | Lymphoma | - | - |
dasatinib | Phase 3 | Myeloid Leukemia, Chronic, Accelerated Phase | - | - |
Paclitaxel | Phase 3 | Breast Cancer | - | - |
Muraglitazar | Phase 3 | Metabolics Diabetes Nos | - | - |
Atazanavir + Ritonavir | Phase 3 | Human Immunodeficiency Virus (HIV) Infections | - | - |
Sorafenib | Phase 3 | Hepatocellular Carcinoma | - | - |
SAR302503 | Phase 3 | Hematopoietic Neoplasm | - | - |
Irbesartan monotherapy | Phase 3 | Hypertension | - | - |
Atazanavir Sulphate | Phase 3 | HIV | - | - |
Pomalidomide | Phase 3 | Multiple Myeloma | - | - |
Asunaprevir (ASV) | Phase 3 | Hepatitis C Virus | - | - |
Antidepressant + Aripiprazole | Phase 3 | Major Depressive Disorder | - | - |
Asunaprevir | Phase 3 | Hepatitis C | - | - |
DCV | Phase 3 | Hepatitis C | - | - |
Relatlimab | Phase 3 | Advanced Gastric Cancer | - | - |
Daclatasvir | Phase 3 | Hepatitis C Infection | - | - |
BMS-986205 | Phase 3 | Advanced Cancer | - | - |
Oral Azacitidine | Phase 3 | Myelodysplastic Syndromes | - | - |
Atazanavir (immediate switch) | Phase 3 | HIV Infections | - | - |
Cabozantinib | Phase 3 | Renal Cell Carcinoma | - | - |
Atazanavir | Phase 3 | HIV Infections | - | - |
Lamivudine/Zidovudine | Phase 3 | HIV Infections | - | - |
Peg-interferon Alfa-2a | Phase 3 | Hepatitis C Virus | - | - |
Gemcitabine | Phase 3 | Stage IV or Recurrent Non-Small Cell Lung Cancer | - | - |
Iza-bren | Phase 3 | Urothelial Cancer | - | - |
vinflunine | Phase 3 | Transitional Cell Carcinoma | - | - |
rHuPH20 | Phase 3 | Melanoma | - | - |
Bempegaldesleukin | Phase 3 | Bladder Cancer | - | - |
Pemetrexed | Phase 3 | Mesothelioma, Malignant | - | - |
Fluorouracil | Phase 3 | Various Advanced Cancer | - | - |
Xanomeline/Trospium Chloride Capsule | Phase 3 | Alzheimer Disease | - | - |
Iberdomide | Phase 3 | Multiple Myeloma | - | - |
Sunitinib | Phase 3 | Advanced Renal Cell Carcinoma | - | - |
Deucravacitinib | Phase 3 | Psoriatic Arthritis | - | - |
Atazanvir/ritonavir + efavirenz | Phase 3 | HIV Infections | - | - |
Belatacept | Phase 3 | Renal Transplantation | - | - |
Tacrolimus | Phase 3 | Renal Allograft Recipients | - | - |
PEG-Interferon alfa 2a | Phase 3 | Hepatitis C, Genotype 1 | - | - |
Docetaxel | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Double-blind Abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
BMS-986165 | Phase 3 | Psoriasis | - | - |
KarXT | Phase 3 | Alzheimer Disease | - | - |
Xanomeline/Trospium Chloride | Phase 3 | Mania | - | - |
Efavirenz | Phase 3 | HIV Infections | - | - |
Xanomeline Enteric Capsule | Phase 3 | Alzheimer Disease | - | - |
BMS-790052 (NS5A Replication Complex Inhibitor) | Phase 3 | Hepatitis C | - | - |
DCV 3DAA | Phase 3 | Hepatitis C Virus Infection | - | - |
Atazanavir + ritonavir + tenofovir + nucleoside | Phase 3 | HIV Infections | - | - |
BMS-986504 | Phase 3 | Metastatic Non-small Cell Lung Cancer With MTAP Deletion | - | - |
Pumitamig | Phase 3 | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | - | - |
Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Phase 3 | Rheumatoid Arthritis | - | - |
Capecitabine | Phase 3 | Gastric Cancer | - | - |
Leucovorin | Phase 3 | Metastatic Colorectal Cancer | - | - |
BMS-936558 | Phase 3 | Unresectable or Metastatic Melanoma | - | - |
Videx EC | Phase 3 | HIV Infections | - | - |
Etoposide | Phase 3 | Small Cell Lung Carcinoma | - | - |
Apremilast | Phase 3 | Psoriatic Arthritis | - | - |
Ustekinumab | Phase 3 | Plaque Psoriasis | - | - |
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) | Phase 3 | Rheumatoid Arthritis | - | - |
Tenofovir | Phase 3 | Chronic Hepatitis B | - | - |
Oxaliplatin | Phase 3 | Colorectal Cancer | - | - |
Imatinib | Phase 3 | Chronic Myeloid Leukemia | - | - |
Telaprevir | Phase 3 | Hepatitis C | - | - |
Cyclosporine (CsA) | Phase 3 | Kidney Transplantation | - | - |
Xanomeline and Trospium Chloride Capsules | Phase 3 | Schizophrenia | - | - |
MDX-010 (anti-CTLA4) monoclonal antibody | Phase 3 | Melanoma | - | - |
Paclitaxel and carboplatin | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Pegylated interferon lambda (pegIFNλ) | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Prednisone | Phase 3 | Prostate Cancer | - | - |
Irbesartan | Phase 3 | Atrial Fibrillation | - | - |
stavudine, efavirenz, lamivudine | Phase 3 | HIV Infections | - | - |
Ribavirin | Phase 3 | Hepatitis C | - | - |
Methotrexate | Phase 3 | Rheumatoid Arthritis | - | - |
DCV/ASV/BMS-791325 | Phase 3 | Hepatitis C Virus | - | - |
Subcutaneous (SC) Abatacept | Phase 3 | Rheumatoid Arthritis (RA) | - | - |
Dacarbazine | Phase 3 | Melanoma | - | - |
Everolimus | Phase 3 | Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma | - | - |
Peginterferon Alfa-2a | Phase 3 | Hepatitis C | - | - |
pexacerfont | Phase 3 | Generalized Anxiety Disorder | - | - |
Didanosine | Phase 3 | HIV Infections | - | - |
Methotrexate (MTX) | Phase 3 | Rheumatoid Arthritis (RA) | - | - |
Irbesartan/HCTZ | Phase 3 | Hypertension | - | - |
Peginterferon Lambda-1a | Phase 3 | Hepatitis C Virus (HCV) | - | - |
atazanavir/ritonavir +2 NRTIs (immediate Switch Group) | Phase 3 | HIV Infections | - | - |
Atazanavir powder | Phase 3 | HIV Infections | - | - |
BMS-986353 | Phase 3 | Systemic Sclerosis | - | - |
Glucovance (metformin HCl/glyburide) | Phase 3 | Diabetes Mellitus, Non-Insulin-Dependent | - | - |
ATV | Phase 3 | HIV Infections | - | - |
Atazanavir+ritonavir | Phase 3 | HIV Infections | - | - |
Lenalidomide | Phase 3 | Multiple Myeloma | - | - |
Bortezomib | Phase 3 | Multiple Myeloma | - | - |
Nelfinavir mesylate | Phase 3 | HIV Infections | - | - |
Tanespimycin | Phase 3 | Advanced Malignancies | - | - |
Brivanib | Phase 3 | Hepato Cellular Carcinoma (HCC) | - | - |
BMS-986278 | Phase 3 | Idiopathic Pulmonary Fibrosis | - | - |
Sofosbuvir | Phase 3 | Hepatitis C | - | - |
Sorivudine | Phase 3 | HIV Infections | - | - |
KarX-EC | Phase 3 | Alzheimer's Disease | - | - |
Pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
warfarin | Phase 3 | Venous Thrombosis | - | - |
Adefovir | Phase 3 | Hepatitis B, Chronic | - | - |
Cyclosporin A | Phase 3 | Renal Transplantation | - | - |
Luspatercept | Phase 3 | Myelodysplastic Syndromes | - | - |
Acetylsalicylic acid | Phase 3 | Atrial Fibrillation | - | - |
abatacept (ABA) | Phase 3 | Ulcerative Colitis | - | - |
pegIFNα-2b | Phase 3 | Hepatitis C Virus Infection | - | - |
Temozolomide | Phase 3 | Brain Cancer | - | - |
nab-Paclitaxel | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Abatacept subcutaneous | Phase 3 | Polymyositis | - | - |
Ozanimod | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
Aurexis® (tefibazumab) | Phase 2 | Staphylococcus Aureus | - | - |
Aurexis® | Phase 2 | Staphylococcus Aureus Bacteremia | - | - |
branebrutinib | Phase 2 | Autoimmune Disorder | - | - |
Vitamin K Antagonist (VKA) | Phase 2 | Thrombosis | - | - |
Cabazitaxel | Phase 2 | Prostate Cancer | - | - |
Letrozole | Phase 2 | Metastatic Breast Cancer | - | - |
CXL-1020 | Phase 2 | Heart Failure | - | - |
Fulvestrant | Phase 2 | Advanced Breast Cancer | - | - |
Oral Taxane | Phase 2 | Non-small Cell Lung Cancer | - | - |
BMS-986253 | Phase 2 | Cancer | - | - |
BMS-986322 | Phase 2 | Psoriasis | - | - |
Doxorubicin | Phase 2 | Hodgkin Disease | - | - |
Pegylated Interferon Lambda | Phase 2 | Hepatitis C | - | - |
BMS-986490 | Phase 2 | Advanced Solid Tumors | - | - |
Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC) | Phase 2 | HIV Infections | - | - |
MYK-491 | Phase 2 | Heart Failure With Reduced Ejection Fraction | - | - |
BMS-986369 | Phase 2 | Relapsed or Refractory T-cell Lymphomas | - | - |
5-fluorouracil (5-FU) | Phase 2 | Colorectal Cancer | - | - |
Peginterferon alpha-2a | Phase 2 | Hepatitis C Infection | - | - |
BMS-777607 | Phase 2 | Advanced Solid Tumors | - | - |
Exemestane + Dasatinib | Phase 2 | Breast Cancer | - | - |
Dasatinib 100 mg | Phase 2 | Breast Cancer | - | - |
BMS-986207 | Phase 2 | Broad Solid Tumor | - | - |
PSI-7977 | Phase 2 | Chronic Hepatitis C | - | - |
Megestrol acetate | Phase 2 | Anorexia | - | - |
Fedratinib | Phase 2 | Primary Myelofibrosis | - | - |
200 mg INX-08189 Fasted | Phase 2 | Hepatitis C | - | - |
BMS-582949 | Phase 2 | Vascular Diseases | - | - |
unfractionated heparin (UFH) | Phase 2 | Antithrombotic | - | - |
Cobimetinib | Phase 2 | Microsatellite Unstable Colorectal Cancer | - | - |
MORAb-202 | Phase 2 | Neoplasms, Ovarian | - | - |
BMS-986523 | Phase 2 | Advanced Solid Malignancies | - | - |
BMS-986259 | Phase 2 | Acute Decompensated Heart Failure | - | - |
BMS-986036 | Phase 2 | Non-Alcoholic Steatohepatitis | - | - |
Afimetoran | Phase 2 | Systemic Lupus Erythematosus | - | - |
MDX-010 | Phase 2 | Breast Cancer | - | - |
BMS-823778 | Phase 2 | Dyslipidemia | - | - |
Lirilumab | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
BMS-986004 75 mg IV | Phase 2 | Immune Thrombocytopenic Purpura | - | - |
Vemurafenib | Phase 2 | Melanoma | - | - |
Duloxetine | Phase 2 | Depression | - | - |
MDX-1100 | Phase 2 | Rheumatoid Arthritis | - | - |
BMS-986231 | Phase 2 | Cardiac Failure | - | - |
BMS-986213 | Phase 2 | Advanced Solid Tumors | - | - |
Trametinib | Phase 2 | Cancer | - | - |
KOS-1584 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
BMS-986158 | Phase 2 | Myelofibrosis | - | - |
BMS-908662 | Phase 2 | Colorectal Cancer | - | - |
INX-08189 50 mg | Phase 2 | Healthy | - | - |
BMS-986020 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
BMS-830216 | Phase 2 | Obesity | - | - |
Strata 1 CXL-1020 | Phase 2 | Heart Failure | - | - |
carboplatin + irinotecan | Phase 2 | Neoplasms | - | - |
BMS-986340 | Phase 2 | Cervical Cancer | - | - |
Anastrozole | Phase 2 | Breast Cancer | - | - |
BMS-986446 | Phase 2 | Alzheimer Disease, Early Onset | - | - |
BMS-936557 (Anti-IP-10 Antibody) | Phase 2 | Crohn's Disease | - | - |
BMS-820836 | Phase 2 | Depression | - | - |
BMS-770767 | Phase 2 | Diabetes Type 2 | - | - |
Pegylated-interferon alfa-2a | Phase 2 | Chronic Hepatitis C | - | - |
SAR302503 (TG101348) | Phase 2 | Myelofibrosis | - | - |
pegIFN | Phase 2 | Hepatitis B Virus | - | - |
HNO Donor | Phase 2 | Heart Failure | - | - |
BMS-986435 | Phase 2 | Heart Failure | - | - |
Thalidomide | Phase 2 | Relapsed and/or Refractory Multiple Myeloma | - | - |
brivanib (active) | Phase 2 | Hepatocellular Carcinoma (HCC) | - | - |
ixabepilone | Phase 2 | Esophageal Cancer | - | - |
BMS-708163 | Phase 2 | Alzheimer's Disease | - | - |
BMS-954561 | Phase 2 | Diabetic Peripheral Neuropathic Pain | - | - |
CCR2 Antagonist | Phase 2 | Type 2 Diabetes | - | - |
Cyclophosphamide | Phase 2 | Breast Cancer | - | - |
BMS-790052 | Phase 2 | Hepatitis C Infection | - | - |
BMS-986142 | Phase 2 | Rheumatoid Arthritis | - | - |
CC-92480 | Phase 2 | Multiple Myeloma | - | - |
BMS-986507 | Phase 2 | Lung Cancer | - | - |
MDX-010 (CTLA-4) | Phase 2 | Melanoma | - | - |
Cabiralizumab | Phase 2 | Advanced Pancreatic Cancer | - | - |
CXL-1427 | Phase 2 | Heart Failure | - | - |
Peginterferon α-2a | Phase 2 | Hepatitis C | - | - |
BMS-986012 (anti-fucosyl-GM1) | Phase 2 | Small Cell Lung Cancer | - | - |
BMS-986449 | Phase 2 | Advanced Solid Tumors | - | - |
BMS-986482 | Phase 2 | Advanced Solid Tumors | - | - |
BMS-791325 | Phase 2 | Hepatitis C Virus | - | - |
Pegylated interferon alfa-2a | Phase 2 | Hepatitis C Virus | - | - |
BMS-986156 | Phase 2 | Solid Tumors | - | - |
MDX-010 / MDX-010 + Docetaxel | Phase 2 | Prostate Cancer | - | - |
Lamivudine | Phase 2 | Hepatitis B Virus | - | - |
BMS-986458 | Phase 2 | Relapsed/Refractory Non-Hodgkin Lymphoma | - | - |
BMS-986517 | Phase 2 | Solid Tumours | - | - |
Cyclosporine | Phase 2 | Graft Rejection | - | - |
Daratumumab | Phase 2 | Advanced Cancer | - | - |
BMS-562086 | Phase 2 | Irritable Bowel Syndrome | - | - |
Irinotecan | Phase 2 | Colorectal Cancer (CRC) | - | - |
BMS-986263 | Phase 2 | Hepatic Cirrhosis | - | - |
Thymoglobulin | Phase 2 | Kidney Transplantation | - | - |
INX-08189 50 mg QD X 5 days | Phase 2 | Healthy | - | - |
BMS-690514 | Phase 2 | Non-Small-Cell Lung Carcinoma | - | - |
Cyclosporine A | Phase 2 | Renal Transplant | - | - |
bendamustine | Phase 2 | Hodgkin Disease | - | - |
Elotuzumab (BMS-901608) | Phase 2 | Multiple Myeloma | - | - |
BMS-986012 | Phase 2 | Extensive-stage Small Cell Lung Cancer | - | - |
Ritonavir | Phase 2 | HIV Infections | - | - |
BMS-833923 | Phase 2 | Leukemia | - | - |
BMS-986165 Dose A | Phase 2 | Active Psoriatic Arthritis | - | - |
Dexamethasone | Phase 2 | Multiple Myeloma | - | - |
Imzokitug | Phase 2 | Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | - | - |
Abatacept (BMS-188667) | Phase 2 | Rheumatoid Arthritis | - | - |
BMS-754807 | Phase 2 | Breast Cancer | - | - |
BMS-986315 | Phase 2 | Advanced Solid Tumor | - | - |
BMS-986288 | Phase 2 | Advanced Cancer | - | - |
BMS-986470 | Phase 2 | Anemia, Sickle Cell | - | - |
BMS-790052 (NS5A Inhibitor) | Phase 2 | Hepatitis C | - | - |
BMS-986525 | Phase 2 | Relapsed/Refractory Small Cell Lung Cancer | - | - |
BMS-813160 | Phase 2 | Advanced Cancer | - | - |
Sirolimus | Phase 2 | Disorder Related to Renal Transplantation | - | - |
BMS-986249 | Phase 2 | Advanced Cancer | - | - |
BMS-914392 | Phase 2 | Atrial Fibrillation | - | - |
BMS-650032 | Phase 2 | Hepatitis C Virus | - | - |
CC-486 | Phase 2 | Leukemia, Myeloid, Acute | - | - |
Erlotinib | Phase 2 | Non Small Cell Lung Cancer | - | - |
Anti-CD137 (4-1BB) (BMS-663513) | Phase 2 | Melanoma | - | - |
BMS-986141 | Phase 2 | Thrombosis | - | - |
Simeprevir | Phase 2 | Hepatitis C Virus | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BRISTOL MYERS SQUIBB CO's drug pipeline?→
CatalystAlert tracks 249 drug candidates in BRISTOL MYERS SQUIBB CO's (CELG-RI) pipeline across Phase 3, Phase 2, Approved. Its lead program is Lithium (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BRISTOL MYERS SQUIBB CO's next FDA catalyst?→
BRISTOL MYERS SQUIBB CO's (CELG-RI) next tracked catalyst is a Phase 3 expected July 25, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CELG-RI biotech catalysts?→
Add CELG-RI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BRISTOL MYERS SQUIBB CO's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.